Braster Valuation

Is BRA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BRA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BRA (PLN0.58) is trading below our estimate of fair value (PLN0.97)

Significantly Below Fair Value: BRA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BRA?

Key metric: As BRA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BRA. This is calculated by dividing BRA's market cap by their current revenue.
What is BRA's PS Ratio?
PS Ratio	8x
Sales	zł2.14m
Market Cap	zł17.04m

BRA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	13.2x
Enterprise Value/EBITDA	-32.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does BRA's PS Ratio compare to its peers?

The above table shows the PS ratio for BRA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	7.3x
NST Nestmedic	15.2x	n/a	zł17.1m
CMI CM International	0.6x	n/a	zł10.8m
MTN Milton Essex Spólka Akcyjna	7.7x	n/a	zł6.2m
MDG Medicalgorithmics	5.5x	n/a	zł194.1m
BRA Braster	8x	n/a	zł17.0m

Price-To-Sales vs Peers: BRA is expensive based on its Price-To-Sales Ratio (8x) compared to the peer average (5.9x).

Price to Sales Ratio vs Industry

How does BRA's PS Ratio compare vs other companies in the European Medical Equipment Industry?

35 Companies	Price / Sales	Estimated Growth	Market Cap

35 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: BRA is expensive based on its Price-To-Sales Ratio (8x) compared to the European Medical Equipment industry average (3.5x).

Price to Sales Ratio vs Fair Ratio

What is BRA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BRA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BRA's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.